STEAP, a prostate tumor antigen, is a target of human CD8+ T cells

Cancer Immunology, Immunotherapy

Volumn 55, Issue 12, 2006, Pages 1515-1523

  Alves, Pedro M S ^a,e   Faure, Olivier ^a,c   Graff Dubois, Stéphanie ^a   Cornet, Sebastien ^a   Bolonakis, Irena ^d   Gross, David Alexandre ^a   Miconnet, Isabelle ^a   Chouaib, Salem ^a   Fizazi, Karim ^a   Soria, Jean Charles ^a   Lemonnier, François A ^b   Kosmatopoulos, Kostas ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT PASTEUR   (France)

^c Immuno Designed Molecules   (France)

^d UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

^e Hopital Orthopedique de la Suisse Romande   (Switzerland)

Author keywords

HLA A*0201 epitopes; STEAP; Tumor antigen

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; GAMMA INTERFERON; HLA A ANTIGEN; LEUCYLLEUCYLLEUCYLGLYCYLTHREONYLISOLEUCYLHISTIDYLALANYLLEUCINE; PHENYLALANYLLEUCYLTYROSYLTHREONYLLEUCYLLEUCYLARGINYLGLUTAMYLVALINE; PROSTATE SPECIFIC ANTIGEN; STEAP ANTIGEN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HLA-A ANTIGENS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33748302110     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0165-3     Document Type: Article

References (29)

1. Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K (2003) Epha2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res 63:8476-8480
2. Andersen MH, Pedersen LO, Becker JC, Straten PT (2001) Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 61:869-872
3. Bai XF, Liu J, Li O, Zheng P, Liu Y (2003) Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 111:1487-1496
4. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365
5. Chen CH, Wu TC (1998) Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 5:231-252
6. Cornet S, Miconnet I, Menez-Jamet J, Lemonnier FA, Kosmatopoulos K (2006) Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity. Vaccine 24:2102-2109
7. Espevik T, Nissen-Meyer J (1986) A highly sensitive cell line, Wehi 164 Clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99-105
8. Faure O, Graff-Dubois S, Bretaudeau L, Derre L, Gross DA, Alves PM, Cornet S, Duffour MT, Chouaib S, Miconnet I, Gregoire M, Jotereau F, Lemonnier FA, Abastado JP, Kosmatopoulos K (2004) Inducible Hsp70 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Int J Cancer 108:863-870
9. Foss FM (2002) Immunologic mechanisms of antitumor activity. Semin Oncol 29:5-11
10. Garcia KC, Teyton L, Wilson IA (1999) Structural basis of T cell recognition. Annu Rev Immunol 17:369-397
11. Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K (2002) Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by Mage-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 169:575-580
12. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DE (1999) STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 96:14523-14528
13. Jung T, Schauer U, Heusser C, Neumann C, Rieger C (1993) Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159:197-207
14. Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L (2005) Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 65:6435-6442
15. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R (2000) Strategies for immunotherapy of cancer. Adv Immunol 75:235-282
16. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA (1998) Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 160:643-651
17. Parham P, Brodsky FM (1981) Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 3:277-299
18. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163-175
19. (+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185:2043-2051
20. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219
21. Ressing ME, Offringa R, Toes RE, Ossendorp F, de Jong JH, Brandt RM, Kast WM, Melief CJ (1996) Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immunotechnology 2:241-251
22. Rodeberg DA, Nuss RA, Elsawa SF, Celis E (2005) Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 11:4545-4542
23. Rudolph MG, Wilson IA (2002) The specificity of TCR/pMHC interaction. Curr Opin Immunol 14:52-65
24. Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K (2001) Identification of HER-2/Neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol 31:3261-3270
25. + T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 60:4845-4849
26. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA (1997) Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185:833-841
27. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA, Kosmatopoulos K (2000) A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-Associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 30:3411-3421
28. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673-679
29. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM (2001) Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 61:5857-5860